Covid-19 roundup: As As­traZeneca deals with vac­cine woes, US turns at­ten­tion to its an­ti­body treat­ment; Mod­er­na dos­es first kids in pe­di­atric vac­cine study 

As coun­tries around the world halt the dis­tri­b­u­tion of As­traZeneca’s Covid-19 vac­cine due to re­ports of blood clots, the US is more fo­cused on the phar­ma’s an­ti­body treat­ment.

The US has se­cured half a mil­lion more dos­es of As­traZeneca’s long-act­ing an­ti­body com­bo AZD7442, build­ing on an ini­tial 100,000-dose deal struck back in Oc­to­ber, the com­pa­ny said on Tues­day. As­traZeneca al­so has a sep­a­rate agree­ment to sup­ply the De­part­ment of De­fense with 100,000 dos­es, bring­ing the US’ to­tal sup­ply or­der to 700,000 dos­es in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER